The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine. ... Moderna logo is seen in Warsaw, Poland on April 9, 2025.

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option.

The Moderna logo is seen at the Moderna campus in Norwood, Massachusetts on on December 2, 2020, where the biotechnology company is mass producing its Covid-19 vaccine. Moderna announced Wednesday ...

Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus ...

Test tubes are seen in front of a displayed Moderna logo in this illustration taken, May 21, 2021. [Photo/Agencies] LOS ANGELES - The US government on Tuesday announced a 176-million-US-dollar ...

Test tubes are seen in front of a displayed Moderna logo in this illustration taken, May 21, 2021. [Photo/Agencies] LOS ANGELES - The US government on Tuesday announced a 176-million-US-dollar ...

Moderna said on Wednesday it has entered into an agreement with private equity firm Blackstone's life science investment platform for a funding of $750 million to develop its mRNA flu vaccines.

American biotech company Moderna on Monday commenced construction on its first pharmaceutical plant in China, with an estimated investment of 3.6 billion yuan ($501 million).

Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of ...

As a result, Moderna stock has lost about a quarter of its value in 2023 alone. If You'd Put $1,000 Into Microsoft Stock 20 Years Ago, Here's What You'd Have Today The company's coronavirus ...

Moderna Inc failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna's COVID-19 vaccine.